



## **DAME EMMA WALMSLEY**

Emma Walmsley was Board Director and CEO of GSK for 9 years, stepping down in December 2025, after delivering a strategic, performance and cultural transformation of the global biopharma company and a step change in its prospects. Previously, she was CEO of GSK Consumer Healthcare, then Chaired the Joint Venture and led the demerger listed as Haleon in 2022, the largest demerger in Europe for 20 years.

Emma is a dedicated advocate for responsible pharma, for science, tech and talent-based innovation, global health equity and investing in the prevention as well as treatment of disease. During her tenure, GSK significantly accelerated R&D and business development investment, delivering a new pipeline of specialty medicines and vaccines focused on Respiratory, Inflammation and Immunology; Oncology; HIV and Infectious Diseases. GSK has upgraded 2031 outlooks to more than £40bn revenue, expects to impact the health of 2.5 billion people this decade and continues to be a leader in the Global Access to Medicines Index, since its inception.

Prior to GSK, Emma spent 17 years at L'Oreal, in Paris, London, New York and Shanghai. She is a Board Director of Microsoft and served previously on the US Business Council Executive Committee, the Stanford Medicine Board of Fellows, and the Board of PhRMA Industry Association. Emma has been a business advisor to three UK Prime Ministers and was a Non-Executive Director of Diageo.

She holds an MA in Classics and Modern Languages from Oxford University and is married with four children.